Hypoprothrombinemia is basically a rare bleeding disorder, which may be acquired or inherited. Under this disorder, a deficiency of the blood-clotting substance prothrombin (Factor II) is produced in the liver. The deficiency further results in a dysfunctional of blood clotting mechanism, leading to an increased physiological risk for spontaneous bleeding.
This report contains market size and forecasts of Hypoprothrombinemia Treatment in Global, including the following market information:
Global Hypoprothrombinemia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hypoprothrombinemia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Type I Deficiency Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hypoprothrombinemia Treatment include Roche, Abbott, Takeda Pharmaceutical Company, CSL Limited, Bayer, Pfizer, Novo Nordisk, Grifols and Biogen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hypoprothrombinemia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hypoprothrombinemia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hypoprothrombinemia Treatment Market Segment Percentages, by Type, 2021 (%)
Type I Deficiency Treatment
Type II Deficiency Treatment
Global Hypoprothrombinemia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hypoprothrombinemia Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Home Care
Specialist Clinic
Global Hypoprothrombinemia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hypoprothrombinemia Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hypoprothrombinemia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hypoprothrombinemia Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Abbott
Takeda Pharmaceutical Company
CSL Limited
Bayer
Pfizer
Novo Nordisk
Grifols
Biogen
BioMarin
BioSyent
Glenmark Pharmaceuticals
Amarna Therapeutics
Alnylam Pharmaceuticals
Teva Pharmaceutical Industries
Mylan
Integra LifeSciences
Enzo Biochem
Emcure
Amgen
Emergent
Baxter
Medtronic
Dr. Reddy’s Laboratories
Amneal Pharmaceuticals
Octapharma
Epitomepharm
Viramal